

STUDY PROTOCOL

Open Access

Observational study on efficacy of negative expiratory pressure test proposed as screening for obstructive sleep apnea syndrome among commercial interstate bus drivers - protocol study

Raquel P Hirata¹, Isabella C Aguiar¹, Sergio R Nacif², Lilian C Giannasi³, Fernando SS Leitão Filho⁴, Israel R Santos¹, Salvatore Romano⁵, Newton S Faria Jr¹, Paula N Nonaka¹, Luciana MM Sampaio¹, Claudia S Oliveira¹, Paulo TC Carvalho¹, Geraldo Lorenzi-Filho⁶, Alberto Braghiroli⁷, Adriana Salvaggio⁵, Giuseppe Insalaco⁵ and Luis VF Oliveira^{1*}

Abstract

Background: Obstructive sleep apnea (OSA) is a respiratory disease characterized by the collapse of the extrathoracic airway and has important social implications related to accidents and cardiovascular risk. The main objective of the present study was to investigate whether the drop in expiratory flow and the volume expired in 0.2 s during the application of negative expiratory pressure (NEP) are associated with the presence and severity of OSA in a population of professional interstate bus drivers who travel medium and long distances.

Methods/Design: An observational, analytic study will be carried out involving adult male subjects of an interstate bus company. Those who agree to participate will undergo a detailed patient history, physical examination involving determination of blood pressure, anthropometric data, circumference measurements (hips, waist and neck), tonsils and Mallampati index. Moreover, specific questionnaires addressing sleep apnea and excessive daytime sleepiness will be administered. Data acquisition will be completely anonymous. Following the medical examination, the participants will perform a spirometry, NEP test and standard overnight polysomnography. The NEP test is performed through the administration of negative pressure at the mouth during expiration. This is a practical test performed while awake and requires little cooperation from the subject. In the absence of expiratory flow limitation, the increase in the pressure gradient between the alveoli and open upper airway caused by NEP results in an increase in expiratory flow.

Discussion: Despite the abundance of scientific evidence, OSA is still underdiagnosed in the general population. In addition, diagnostic procedures are expensive, and predictive criteria are still unsatisfactory. Because increased upper airway collapsibility is one of the main determinants of OSA, the response to the application of NEP could be a predictor of this disorder. With the enrollment of this study protocol, the expectation is to encounter predictive NEP values for different degrees of OSA in order to contribute toward an early diagnosis of this condition and reduce its impact and complications among commercial interstate bus drivers.

Trial registration: *Registro Brasileiro de Ensaio Clínicos* (local acronym RBEC) [Internet]: Rio de Janeiro (RJ): *Instituto de Informação Científica e Tecnológica em Saúde* (Brazil); 2010 - Identifier RBR-7dq5xx. Cross-sectional study on efficacy of negative expiratory pressure test proposed as screening for obstructive sleep apnea syndrome among commercial interstate bus drivers; 2011 May 31 [7 pages]. Available from <http://www.ensaiosclinicos.gov.br/rg/RBR-7dq5xx/>.

* Correspondence: oliveira.lvf@pq.cnpq.br

¹Master's and Doctoral Degree Programs in Rehabilitation Sciences, Nove de Julho, University, Sao Paulo, Brazil

Full list of author information is available at the end of the article

Background

Sleep disorders are common throughout the world and have living effects on modern industrialized “24-hour” societies. The consequences of such disorders include excessive sleepiness, a negative effect on social and recreational activities, a decreased physical ability, a decline in productivity and a high risk of accidents [1]. These conditions, which are associated to acute or chronic insomnia, chronic sleep restriction, work shifts, jet lag, narcolepsy and obstructive sleep apnea (OSA), are a public health concern.

There is a large body of evidence demonstrating that sleepiness contributes toward industrial and traffic accidents [2]. It has previously been reported that 22% of accidents are caused by excessive sleepiness and 17-19% of traffic deaths are the result of sleepiness at the wheel [3]. The medical and economic costs of traffic accidents are estimated to be 1 to 3% of the gross domestic product of a country (annual cost of approximately 518 billion dollars). The *Instituto de Pesquisa Econômica Aplicada* (IPEA) [Institute of Applied Economic Research] of the Brazilian Federal Government reports that the mean cost of traffic accidents in Brazil is US\$ 5,167,000, among which US\$ 1,919,000 are spent on victimless accidents, US\$ 2,942,000 are spent on accidents that result in injuries and US\$ 2,476,000 are spent on accidents involving deaths [4].

OSA is a respiratory disease characterized by the collapse of the upper airways which occurs during sleep in predisposed subjects. Following chronic obstructive pulmonary disease and asthma, OSA is the epidemiological most important and widespread respiratory disease, affecting 3 to 7% of the male population and 2 to 5% of the female population between 40 and 65 years of age in the western world [5]. In Brazil, prevalence even larger was encountered according to an epidemiological study carried out in the city of Sao Paulo, where 24.8% males and 9.6% females were OSA patients [6].

One of the most important social implications of OSA is the increased risk for driving accidents [7]. Pack et al. (2002) reported a prevalence of 28% in a population of professional truck drivers [8]. The main cause of road accidents among professional drivers is lack of sleep, disturbance in the sleep/wake cycle (shift workers) and sleep disorders [9,10].

There is a close relationship between OSA and the risk of cardiovascular disease [11-13], neuropsychological problems [14,15], reduction in quality of life [16,17] and increase in the use of health resources [18,19], demonstrating that, when under-diagnosed, OSA can have serious consequences. Thus, the identification of new markers for OSA can be of considerable relevance for clinical practice.

An increase in the upper airway collapsibility is one of the main determinants of OSA [20,21]. Investigators have identified anatomical factors [22-24], neuromuscular control factors [25,26] and liquid and fat deposits [27] that may lead to increased pharyngeal collapsibility during sleep.

The negative expiratory pressure (NEP) method was initially used to assess intrathoracic expiratory flow limitations in patients with chronic obstructive pulmonary disease [28]. However, NEP test in individuals with OSA was found to lead to a collapse of the extrathoracic airway, with a drop in expiratory flow below the preceding expiration, which is common among patients with OSA [29-32]. The NEP test is carried out by administering negative pressure at the mouth during expiration. This maneuver is easy to perform and requires minimal patient cooperation. NEP test is based on the pressure gradient increase between the alveoli and open upper airway that results in an increase in expiratory flow. This study will allow the use of new screening technique to detect upper airway collapsibility, a high risk indicator for OSA in professional drivers. It's a daytime, low-cost screening method that could be included in a preventive strategy aimed at reducing the impact of this condition on accidents and the development of cardiovascular consequences.

Objectives

The main objective of the study, which will be conducted on medium and long distance professional interstate bus drivers, is to investigate whether NEP test induced upper airway collapse is indicative for the presence and severity of OSA. Secondary objectives are: 1) identify the prevalence of OSA in this population; 2) determine the prevalence of metabolic syndrome and cardiovascular disease; 3) determine the correlation of work shift on clinical findings; and 4) validate a novel questionnaire on sleep quality proposed by the *Italian National Research Council Institute of Biomedicine and Molecular Immunology* “A. Monroy” and *Centro Medico di Veruno* (Italy).


Methods/Design

Study design

An observational, analytical study will be carried out at the Sleep Laboratory of the Master's and Doctoral Postgraduate Program in Rehabilitation Sciences of the Nove de Julho University (Brazil) (Figure 1). The design, conduction and reporting of this study will follow the norms of the “Standards for the Reporting of Diagnostic accuracy studies” - STARD statement.

Subjects

Male professional bus drivers of an interstate roadway firm will be invited to participate in the study. The



community-based sample includes shift workers: individuals working regular night shifts (from 10:00 pm to 08:00 am), individuals working regular day shifts (from 08:00 am to 06:00 pm), and subjects working rotating shifts.

With regard to the inclusion criteria, the sample will be made up by medium and long distance drivers, agreeing to participate in the study through a signed informed consent form. Subjects with acute pulmonary or heart disease and/or major cranio-facial or upper airway abnormalities, drug users and alcoholics will be excluded from the study.

Protocol

The initial population of professional bus drivers includes 710 subjects. All will be asked to be part of the study and all procedures will be clarified. Those who agree to participate will undergo a detailed patient history, physical examination involving determination of blood pressure, anthropometric data, circumference measurements (hips, waist and neck), tonsils and Mallampati index. Moreover, specific questionnaires addressing sleep apnea and excessive daytime sleepiness will be administered. Data acquisition will be completely anonymous. Following the medical examination, the

participants will perform a spirometry, NEP test and standard overnight polysomnography.

Physical examination

Weight and height evaluation will be performed through an electronic balance (model 200/5, Welmy Industria e Comercio Ltda, Sao Paulo, Brazil) and body mass index (BMI) will be calculated [33]. For the assessments of tonsils and Mallampati index, subjects will be in the sitting position and instructed to open the mouth as much as possible [34,35].

Waist circumference will be measured with the subject in the upright position, standing at the midpoint between the costal margin and the iliac crest at the end of normal expiration. The hip circumference will be measured with the subject in the same position at the level of the greater trochanter. Neck circumference will be measured with the subject in the sitting position at the edge of the cricoid cartilage.

OSA and excessive daytime sleepiness questionnaires

The Berlin Questionnaire will be administered. This 10-item questionnaire has recognized efficacy in distinguishing subjects at greater risk for OSA in primary care population [36]. The Epworth Sleepiness Scale [37] will be used for the assessment of excessive daytime sleepiness. Moreover, a novel OSA questionnaire designed by researchers of the Italian National Research Council - Institute of Biomedicine and Molecular Immunology "A. Monroy" and Centro Medico di Veruno will be administered.

Spirometry

The spirometry will be carried out during the day, with the patient seated in a comfortable position. For such, the KoKo PFT System Version 4.11 (nSpire Health, Inc; Louisville, CO, USA) will be used following national guidelines for the execution of lung function tests by the Brazilian Society of Pneumology [38] and the European Respiratory Society [39]. The subjects will perform the test in a comfortable position, with the body erect and the upper limbs unsupported. All examinations will be carried out by a competent technician trained in obtaining the necessary cooperation from the subjects and appropriately operating the equipment in order to ensure accurate, reproducible results. The equipment will be calibrated prior to each exam with a 3-L syringe [38].

Negative expiratory pressure - NEP test

The NEP test is performed through the administration of negative pressure at the mouth during expiration. This is a practical test performed while awake and requires little cooperation from the subject. In the

absence of expiratory flow limitation, the increase in the pressure gradient between the alveoli and open upper airway caused by NEP results in an increase in expiratory flow.

NEP will be generated by a Super Air Amplifier (Exair model 120021 Cincinnati, Ohio, USA) coupled to a tank of compressed air via an electrically operated solenoid valve (Norgren Ltd model 95004; Vimercate, MI, Italy) automatically activated in early expiration and kept open for 2 s by software control (Figure 2). A pneumotachograph (Hans Rudolph model 3830; Kansas City, MO, USA) will be connected to the air amplifier and the mouthpiece to measure airflow (\dot{V}) with pressure transducers (PCLA02X5; Sontortech GmbH, Puchheim, Germany). Mouth pressure will be measured by pressure transducers (PCLA0050; Sontortech GmbH, Puchheim, Germany). NEP of 10 cm H₂O will be set by occluding the pneumotachograph with a stopper and adjusting the flow of compressed air to air amplifier (Figure 2).

NEP maneuvers will be performed (each after at least four breaths to normalize the breathing pattern). The tests will be carried out once with the subjects seated comfortably and one other in supine position on a cot. In both positions, care will be taken to maintain the subjects comfortable with the neck in a neutral position, as it has been documented that the position of the head exerts an influence over upper airway collapsibility [40]. All maneuvers will be performed with the subjects awake and wearing a nose clip. The airflow and the mouth pressure signals will be low-pass filtered and sampled at 200 Hz. Both digital signals will be displayed in real time on the monitor and stored on the computer for subsequent analysis. Signal analysis and solenoid





Figure 2 Schematic representation of the negative expiratory pressure apparatus.

valve control will be performed using software written in Labview 8.2 (National Instruments) developed by the Italian National Research Council, Institute of Biomedicine and Molecular Immunology "A. Monroy".

NEP application during tidal expiration produces an immediate peak flow followed by a sudden drop of a variable degree. Upper airway collapsibility is evaluated by measuring flow limitation as flow drop ($\Delta\dot{V}$), expressed as the percentage of peak flow immediately after NEP administration. To avoid reflex and voluntary reactions to the NEP stimulus, the minimal flow will be identified in the first 200 ms of NEP administration [41]. Upper airway collapsibility is also evaluated by measuring $V_{0.2}$ immediately after NEP administration (Figure 3). These values are expressed as the percentage of mean inspiratory volume of the three breaths preceding NEP administration. Measured volumes are accepted only when differences between inspiration and expiration for each of the three previous breaths are less than 10%. Values of $V_{0.2}$ and $\Delta\dot{V}$ (%) are calculated as the mean of four measurements.

Standard overnight polysomnography

Nocturnal polysomnography will be carried out using the Embla Somnologica Studio - EMBLA A10, version 3.1.2. (Flaga hf. Medical Devices, Iceland) sleep analysis system. The following signals will be recorded: electroencephalogram (F4-M1, C4-M1, O2-M1, and backup electrodes F3, C3, O1 and M2), electrooculograms (E1-M2, E2-M2), chin and tibialis electromyography, electrocardiogram, oxygen saturation, pulse rate, oronasal air flow (nasal cannula and thermistor), respiratory effort (thoracic and abdominal Xtrace model straps), snoring, and body position. The patients will be instructed to remain relaxed and sleep naturally as at home. Throughout the night, the subjects will be monitored by a technician experienced in polysomnography [42]. The reading will be performed by professionals who were



blinded to the result of the NEP test, following the guidelines of the American Academy of Sleep Medicine [43] and criteria of the Brazilian Sleep Society.

Apneas are defined as lack of airflow or a reduction $\geq 90\%$ in the airflow signal for at least 10 s. Hypopneas are defined as discernible drop in flow by $\geq 30\%$ of baseline for a period lasting at least 10 s followed by a SaO_2 fall $\geq 4\%$. AHI will be calculated as number of (apneas + hypopneas)/h of total sleep time. Subjects with AHI ≥ 5 will be classified as OSA [42,43].

Quality control

In order to ensure data quality, the physiotherapists and physicians in charge of data collection will receive specific training. Periodic external monitoring will be performed to verify adequate application of methodology in performing examinations and data collection.

Calculation of sample size and statistical analysis

The calculation of sample size was based on the correlation reported by Insalaco et al. [44] between $\Delta\dot{V}$ (%) and AHI in patients with OSA ($r = 0.37$). For a bidirectional alpha value of 0.05 and 90% power, a minimum number of 82 subjects will be necessary.

Kolmogorov-Smirnov normality test will first be performed in order to determine the presence or absence of a normal distribution sample. Descriptive analysis will be performed, with the data expressed as either mean and standard deviation or median values and 95% confidence intervals, when appropriate. One-way analysis of variance (ANOVA) will be used for comparisons between work shifts once the samples have a normal distribution. $V_{0.2}$ and $\Delta\dot{V}$ (%) values will be linearly correlated with the AHI, for which either Pearson's or Spearman's correlation test will be used, depending on the sample distribution. Either the non-paired Student's t-test or Mann-Whitney test will be used for comparisons between individuals with and without OSA. Logistic regression for the analysis of continuous factors with categorical responses will be performed. Receiver operating characteristic (ROC) curves will be constructed to determine the sensitivity (true positive rate) versus 100-specificity (false positive rate) at various levels of the measured $\Delta\dot{V}$ (%) and $V_{0.2}$ (%) to identify the cut-off value yielding the largest number of correctly classified patients. The statistical analysis will be performed by an experienced statistician using the JMP commercial program (version 8.0, SAS Institute Inc.) and SPSS program (version 16.0, Somers NY). A 5% level of significance and 95% confidence interval will be applied.

Ethical considerations

The present study is in accordance with the Helsinki Declaration and the Regulatory Guidelines and Norms

for Research Involving Human Subjects of the National Health Board of the Brazilian Health Ministry issued in October 1996. This study received approval from the Human Research Ethics Committee of the Nove de Julho University (Brazil) under process number 329445/2010. Informed consent will be required to all subjects.

All procedures of the study will be confidential. The professional drivers diagnosed for OSA will be referred to the Sleep Medicine service and immediately forwarded to adequate treatment in order to treat the sleep respiratory disorder.

Discussion

Despite the abundance of scientific evidence, OSA is still underdiagnosed in the general population. This is probably due to multiple causes, such as deficiency of knowledge on the part of physicians and also the limited access of the patients to diagnosis and treatment of OSA [45]. In addition, diagnostic procedures are expensive, and predictive criteria are still unsatisfactory. Obesity parameters are important predictors, although not all OSA patients are obese and not all obese subjects have OSA. The identification of new markers of OSA would be useful.

The aim of the present protocol study is to determine whether the NEP test could be used as a screening tool for OSA and the prevalence of this condition among a population of professional interstate bus drivers. Because increased upper airway collapsibility is one of

the main determinants of OSA [21], the response to the application of NEP could be a predictor of this disorder.

With the enrollment of this study protocol, the expectation is to encounter predictive NEP values for different degrees of OSA. It's a daytime, low-cost screening method that could be included in a preventive strategy in order to contribute toward an early diagnosis of this condition and reduce its impact and complications among professional interstate bus drivers.

Acknowledgements

The Sleep Laboratory receives funding from the Nove de Julho University (Brazil) and research projects approved by the Brazilian fostering agencies *Fundação de Amparo a Pesquisa do Estado de São Paulo* (local acronym FAPESP) (protocol number 2003/01810-4) and *Conselho Nacional de Desenvolvimento Científico e Tecnológico* (local acronym CNPq) (Research Productivity modality - process number 307618/2010-2). GI, AS and SR are researchers from Italian National Research Council Institute of Biomedicine and Molecular Immunology "A. Monroy". The authors are grateful to the roadway transportation company that allowed the development of this protocol study.

Author details

¹Master's and Doctoral Degree Programs in Rehabilitation Sciences, Nove de Julho, University, São Paulo, Brazil. ²Pulmonary Division, Servidor Público do Estado de São Paulo Hospital, São Paulo, Brazil. ³School of Dentistry, Julio Mesquita Filho State University, São José dos Campos, Brazil. ⁴Department of

Medicine, Fortaleza University, Fortaleza, Brazil. ⁵National Research Council of Italy, Institute of Biomedicine and Molecular Immunology "A. Monroy", Palermo, Italy. ⁶Sleep Laboratory, Pulmonary Division, Heart Institute (InCor) São Paulo University, Medicine School, São Paulo, Brazil. ⁷Sleep Laboratory, Medical Center of Veruno, Salvatore Maugeri Foundation, Veruno (NO) Italy.

Authors' contributions

LVFO, GI and RPH provided the idea for the study, established the hypothesis and wrote the original proposal. SR, GI and AS developed the NEP system and software used in this protocol. RPH, IRS, ICA, NSFJ, LCG, PNN and SRN took part in the data collection. ICA, NSFJ, CSO, PTC and IRS participated in the organization and reporting of the data. FSSLF, LMMS, SR, LCG and SRN worked on the data collection, statistical analysis, evaluation and presentation of the results. RPH, AB and LVFO significantly contributed to writing this protocol paper with the input of all co-authors, while GI, AS, FSSLF, GLF and LMMS were involved in critically revising the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 21 September 2011 Accepted: 7 December 2011
Published: 7 December 2011

References

1. Pandi-Perumal SR, Verster JC, Kayumov L, Lowe AD, Santana MG, Pires ML, Tufik S, Mello MT: **Sleep disorders, sleepiness and traffic safety: a public health menace.** *Braz J Med Biol Res* 2006, **39**(7):863-871.
2. Connor J, Norton R, Ameratunga S, Robinson E, Wigmore B, Jackson R: **Prevalence of driver sleepiness in a random population-based sample of car drivers.** *Sleep* 2001, **24**(6):688-694.
3. Garbarino S: **[Sleep disorders and road accidents in truck drivers].** *G Ital Med Lav Ergon* 2008, **30**(3):291-296.
4. Instituto de Pesquisa Econômica Aplicada I: *In Impactos sociais e econômicos dos acidentes de trânsito nas aglomerações urbanas. Volume 21.* Brasília; 2001.
5. Punjabi NM: **The epidemiology of adult obstructive sleep apnea.** *Proc Am Thorac Soc* 2008, **5**(2):136-143.
6. Tufik S, Santos-Silva R, Taddei JA, Bittencourt LR: **Obstructive sleep apnea syndrome in the São Paulo Epidemiologic Sleep Study.** *Sleep Med* 2010, **11**(5):441-446.
7. Sassani A, Findley LJ, Kryger M, Goldlust E, George C, Davidson TM: **Reducing motor-vehicle collisions, costs, and fatalities by treating obstructive sleep apnea syndrome.** *Sleep* 2004, **27**(3):453-458.
8. Pack AI, Dinges D, Maislin G: **A study of prevalence of sleep apnea among commercial truck drivers.** *Federal Motor Carrier Safety Administration Publication, Washington, DC* 2002, DOT-RT-02-030.
9. Aguiar M, Valença J, Felizardo M, Caeiro F, Moreira S, Staats R, Bugalho de Almeida AA: **Obstructive sleep apnoea syndrome as a cause of road traffic accidents.** *Rev Port Pneumol* 2009, **15**(3):419-431.
10. Sallinen M, Harma M, Mutanen P, Ranta R, Virkkala J, Müller K: **Sleepiness in various shift combinations of irregular shift systems.** *Ind Health* 2005, **43**(1):114-122.
11. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG: **Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study.** *JAMA* 2000, **283**(14):1829-1836.
12. Peker Y, Hedner J, Kraiczi H, Loth S: **Respiratory disturbance index: an independent predictor of mortality in coronary artery disease.** *Am J Respir Crit Care Med* 2000, **162**(1):81-86.
13. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G: **Early signs of atherosclerosis in obstructive sleep apnea.** *Am J Respir Crit Care Med* 2005, **172**(5):613-618.
14. Kim HC, Young T, Matthews CG, Weber SM, Woodward AR, Palta M: **Sleep-disordered breathing and neuropsychological deficits. A population-based study.** *Am J Respir Crit Care Med* 1997, **156**(6):1813-1819.
15. Sharma H, Sharma SK, Kadiravan T, Mehta M, Sreenivas V, Gulati V, Sinha S: **Pattern & correlates of neurocognitive dysfunction in Asian Indian adults with severe obstructive sleep apnoea.** *Indian J Med Res* 2010, **132**:409-414.
16. Flemons WW, Tsai W: **Quality of life consequences of sleep-disordered breathing.** *J Allergy Clin Immunol* 1997, **99**(2):S750-756.

17. Baldwin CM, Ervin AM, Mays MZ, Robbins J, Shafazand S, Walsleben J, Weaver T: **Sleep disturbances, quality of life, and ethnicity: the Sleep Heart Health Study.** *J Clin Sleep Med* 2010, **6**(2):176-183.
18. Smith R, Ronald J, Delaive K, Walld R, Manfreda J, Kryger MH: **What are obstructive sleep apnea patients being treated for prior to this diagnosis?** *Chest* 2002, **121**(1):164-172.
19. Otake K, Delaive K, Walld R, Manfreda J, Kryger MH: **Cardiovascular medication use in patients with undiagnosed obstructive sleep apnoea.** *Thorax* 2002, **57**(5):417-422.
20. Gold AR, Schwartz AR: **The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically.** *Chest* 1996, **110**(4):1077-1088.
21. Fogel RB, Malhotra A, White DP: **Sleep. 2: pathophysiology of obstructive sleep apnoea/hypopnoea syndrome.** *Thorax* 2004, **59**(2):159-163.
22. Bradley TD, Brown IG, Grossman RF, Zamel N, Martinez D, Phillipson EA, Hoffstein V: **Pharyngeal size in snorers, nonsnorers, and patients with obstructive sleep apnea.** *N Engl J Med* 1986, **315**(21):1327-1331.
23. Schwab RJ, Gefter WB, Hoffman EA, Gupta KB, Pack AI: **Dynamic upper airway imaging during awake respiration in normal subjects and patients with sleep disordered breathing.** *Am Rev Respir Dis* 1993, **148**(5):1385-1400.
24. Schellenberg JB, Maislin G, Schwab RJ: **Physical findings and the risk for obstructive sleep apnea. The importance of oropharyngeal structures.** *Am J Respir Crit Care Med* 2000, **162**(2 Pt 1):740-748.
25. Anch AM, Remmers JE, Sauerland EK, Degroot WJ: **Oropharyngeal patency during walking and sleep in the Pickwickian syndrome: electromyographic activity of the tensor veli palatini.** *Electromyogr Clin Neurophysiol* 1981, **21**(2-3):317-330.
26. Fogel RB, Malhotra A, Pillar G, Edwards JK, Beauregard J, Shea SA, White DP: **Genioglossal activation in patients with obstructive sleep apnea versus control subjects. Mechanisms of muscle control.** *Am J Respir Crit Care Med* 2001, **164**(11):2025-2030.
27. Brennick MJ, Pack AI, Ko K, Kim E, Pickup S, Maislin G, Schwab RJ: **Altered upper airway and soft tissue structures in the New Zealand Obese mouse.** *Am J Respir Crit Care Med* 2009, **179**(2):158-169.
28. Koulouris NG, Valtà P, Lavoie A, Corbeil C, Chasse M, Braidy J, Milic-Emili J: **A simple method to detect expiratory flow limitation during spontaneous breathing.** *Eur Respir J* 1995, **8**(2):306-313.
29. Baydur A, Wilkinson L, Mehdian R, Bains B, Milic-Emili J: **Extrathoracic expiratory flow limitation in obesity and obstructive and restrictive disorders: effects of increasing negative expiratory pressure.** *Chest* 2004, **125**(1):98-105.
30. Van Meerhaeghe A, Delpire P, Stenuit P, Kerkhofs M: **Operating characteristics of the negative expiratory pressure technique in predicting obstructive sleep apnoea syndrome in snoring patients.** *Thorax* 2004, **59**(10):883-888.
31. Liistro G, Veriter C, Dury M, Aubert G, Stanesco D: **Expiratory flow limitation in awake sleep-disordered breathing subjects.** *Eur Respir J* 1999, **14**(1):185-190.
32. Verin E, Tardif C, Portier F, Similowski T, Pasquis P, Muir JF: **Evidence for expiratory flow limitation of extrathoracic origin in patients with obstructive sleep apnoea.** *Thorax* 2002, **57**(5):423-428.
33. WHO: **Obesity: preventing and managing the global epidemic. Report of a WHO Consultation.** *WHO Technical Report Series 894* Geneva World Health Organization; 2000.
34. Brodsky L: **Modern assessment of tonsils and adenoids.** *Pediatr Clin North Am* 1989, **36**(6):1551-1569.
35. Mallampati SR, Gatt SP, Gugino LD, Desai SP, Waraksa B, Freiburger D, Liu PL: **A clinical sign to predict difficult tracheal intubation: a prospective study.** *Can Anaesth Soc J* 1985, **32**(4):429-434.
36. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP: **Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome.** *Ann Intern Med* 1999, **131**(7):485-491.
37. Johns MW: **A new method for measuring daytime sleepiness: the Epworth sleepiness scale.** *Sleep* 1991, **14**(6):540-545.
38. Pereira CAC: **II Consenso Brasileiro de Espirometria.** *J Pneumol* 2002, **28**(supl3):S1-S82.
39. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: **Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.** *Eur Respir J Suppl* 1993, **16**:5-40.
40. Isono S, Tanaka A, Tagaito Y, Ishikawa T, Nishino T: **Influences of head positions and bite opening on collapsibility of the passive pharynx.** *J Appl Physiol* 2004, **97**(1):339-346.
41. Romano S, Salvaggio A, Hirata RP, Lo Bue A, Picciolo S, Oliveira LVF, Insalaco G: **Upper airway collapsibility evaluated by negative expiratory pressure test in severe obstructive sleep apnea.** *Clinics* 2011, **66**(5):6.
42. **Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force.** *Sleep* 1999, **22**(5):667-689.
43. **American Academy of Sleep Medicine: The AASM Manual for the scoring of sleep and associated events. Rules, terminology and technical specifications 2007.**
44. Insalaco G, Romano S, Marrone O, Salvaggio A, Bonsignore G: **A new method of negative expiratory pressure test analysis detecting upper airway flow limitation to reveal obstructive sleep apnea.** *Chest* 2005, **128**(4):2159-2165.
45. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD: **High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.** *J Hypertens* 2001, **19**(12):2271-2277.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2466/11/57/prepub>

doi:10.1186/1471-2466-11-57

Cite this article as: Hirata et al.: Observational study on efficacy of negative expiratory pressure test proposed as screening for obstructive sleep apnea syndrome among commercial interstate bus drivers - protocol study. *BMC Pulmonary Medicine* 2011 **11**:57.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

